Diligence memo · auto-generated · as of July 2, 2026
Revi Life Sciences, Inc.
Revi Life Sciences, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Revi Life Sciences, Inc. operates in Biotechnology, based in AUSTIN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Revi Life Sciences, Inc. has raised $340K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $340K on 2025-01-22.
Most recent recorded round closed around 2025-01-22.
Valuation (modeled)modeled
Provath models Revi Life Sciences, Inc. at approximately $1.1M (range $181K–$3.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.16× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era. Within the normal band (116% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 8% of Biotechnology peers (4293 compared).
Modeled value ranks above 3% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.